Global Intravenous (IV) Iron Drugs Market: Analysis By Therapeutic Application, By Product Type, By Region, By Country (2018 Edition): Forecast to 2022
Executive Summary
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global I.V. Iron Drugs Market by Therapeutic Application (Nephrology, Gynecology & Obstetrics, Gastroenterology, Oncology, Cardiology, Others), By Product Type (Ferric carboxymaltose, Iron Sucrose, Iron Dextran and Others) for the regions (North America, Europe, Asia—Pacific and ROW) and By Country (U.S., Canada, U.K., Germany, France, China, India, Japan, Brazil, South Africa).
Over the recent years, the global Intravenous (IV) Iron Drug industry has been driven by the rising high prevalence of Iron Deficiency with unfulfilled need, rising awareness, growing prevalence of diseases leading to severe Iron Deficiency and increasing healthcare expenditure in emerging economies. Globally, the growth in IV Iron drug market is driven by growing middle class population group demanding better drugs to improve lifestyle.
According to Azoth Analytics research report, “Global Intravenous (IV) Iron Drugs Market: Analysis By Therapeutic Application (Nephrology, Gynecology & Obstetrics, Gastroenterology, Oncology, Cardiology, Others), By Product Type (Ferric Carboxymaltose, Iron Sucrose, Iron Dextran, Others) - By Region, By Country (2017-2022)”, global market is projected to display a robust growth represented by a CAGR of 11.19% by value during 2017 – 2022, chiefly driven by increase in healthcare spending and rising prevalence of diseases with Iron deficiency, emerging second & third generation IV Iron drugs and growing middle class income group coupled with rising health consciousness.
Among the therapeutic application type, nephrology accounts for the major market share and anticipated to witness significant growth rate during the forecast period. Among the regions, Asia Pacific is predicted to advance at the highest rate, mainly driven by large population suffering with Iron Deficiency and unfulfilled need, improving access to healthcare, changing lifestyle and expanding middle class income group.
The report titled, “Global Intravenous (IV) Iron Drugs Market: Analysis By Therapeutic Application (Nephrology, Gynecology & Obstetrics, Gastroenterology, Oncology, Cardiology, Others), By Product Type (Ferric Carboxymaltose, Iron Sucrose, Iron Dextran, Others) - By Region, By Country (2017-2022)” has covered and analysed the potential of IV Iron Drug Market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global IV Iron Drug market. Additionally, the report also highlights market entry strategies for various companies across the globe.
Scope of the Report
Global Market (Actual Period: 2012-2016, Forecast Period: 2017-2022)
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
A comprehensive research report created through extensive primary research (inputs from industry experts, companies, stakeholders) and secondary research, the report aims to present the analysis of Global I.V. Iron Drugs Market by Therapeutic Application (Nephrology, Gynecology & Obstetrics, Gastroenterology, Oncology, Cardiology, Others), By Product Type (Ferric carboxymaltose, Iron Sucrose, Iron Dextran and Others) for the regions (North America, Europe, Asia—Pacific and ROW) and By Country (U.S., Canada, U.K., Germany, France, China, India, Japan, Brazil, South Africa).
Over the recent years, the global Intravenous (IV) Iron Drug industry has been driven by the rising high prevalence of Iron Deficiency with unfulfilled need, rising awareness, growing prevalence of diseases leading to severe Iron Deficiency and increasing healthcare expenditure in emerging economies. Globally, the growth in IV Iron drug market is driven by growing middle class population group demanding better drugs to improve lifestyle.
According to Azoth Analytics research report, “Global Intravenous (IV) Iron Drugs Market: Analysis By Therapeutic Application (Nephrology, Gynecology & Obstetrics, Gastroenterology, Oncology, Cardiology, Others), By Product Type (Ferric Carboxymaltose, Iron Sucrose, Iron Dextran, Others) - By Region, By Country (2017-2022)”, global market is projected to display a robust growth represented by a CAGR of 11.19% by value during 2017 – 2022, chiefly driven by increase in healthcare spending and rising prevalence of diseases with Iron deficiency, emerging second & third generation IV Iron drugs and growing middle class income group coupled with rising health consciousness.
Among the therapeutic application type, nephrology accounts for the major market share and anticipated to witness significant growth rate during the forecast period. Among the regions, Asia Pacific is predicted to advance at the highest rate, mainly driven by large population suffering with Iron Deficiency and unfulfilled need, improving access to healthcare, changing lifestyle and expanding middle class income group.
The report titled, “Global Intravenous (IV) Iron Drugs Market: Analysis By Therapeutic Application (Nephrology, Gynecology & Obstetrics, Gastroenterology, Oncology, Cardiology, Others), By Product Type (Ferric Carboxymaltose, Iron Sucrose, Iron Dextran, Others) - By Region, By Country (2017-2022)” has covered and analysed the potential of IV Iron Drug Market and provides statistics and information on market size, shares and growth factors. The report intends to provide cutting-edge market intelligence and help decision makers take sound investment evaluation. Besides, the report also identifies and analyses the emerging trends along with major drivers, challenges and opportunities in the global IV Iron Drug market. Additionally, the report also highlights market entry strategies for various companies across the globe.
Scope of the Report
Global Market (Actual Period: 2012-2016, Forecast Period: 2017-2022)
- Global IV Iron Drug Market, By Value
- By Therapeutic Application (Nephrology, Gynecology & Obstetrics, Gastroenterology, Oncology, Cardiology, Others); By Value
- By Product Type (Ferric carboxymaltose, Iron Sucrose, Iron Dextran and Others), By Value
- By Therapeutic Application (Nephrology, Gynecology & Obstetrics, Gastroenterology, Oncology, Cardiology, Others); By Value
- By Product Type (Ferric carboxymaltose, Iron Sucrose, Iron Dextran and Others), By Value
- By Therapeutic Application (Nephrology, Gynecology & Obstetrics, Gastroenterology, Oncology, Cardiology, Others); By Value
- By Product Type (Ferric carboxymaltose, Iron Sucrose, Iron Dextran and Others), By Value
- Market Dynamics – Trends, Drivers, Challenges, Policy and Regulation
- Company Analysis – Galenica; AMAG Pharmaceuticals, Inc; PHARMACOSMOS A/S; Allergan PLC; DAIICHI SANKYO COMPANY, LIMITED; NIPPON SHINYAKU CO., LTD and Sanofi
The report could be customized according to the client’s specific research requirements. No additional cost will be required to pay for limited additional research.
1. RESEARCH METHODOLOGY
2. EXECUTIVE SUMMARY
3. STRATEGIC RECOMMENDATIONS
3.1. Asia Pacific Region to witness the fastest growth for I.V. Iron drug in the forecast period
3.2. Oncology & cardiology segments are witnessing fastest growth
4. I.V. IRON DRUG MARKET OUTLOOK
5. GLOBAL I.V. IRON DRUG MARKET: GROWTH AND FORECAST
5.1. I.V. Iron Drug Market, By Value (2012-2016)
5.2. I.V. Iron Drug Market, By Value (2017-2022)
5.3. Global I.V. Iron Drug & Market - By Therapeutic Application, By Value
5.3.1. I.V. Iron Drug, By Value, % (2016)
5.3.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
5.4. Global I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
5.4.1. Nephrology, By Value (2012-2022)
5.4.2. Gynecology & Obstetrics, By Value (2012-2022)
5.4.3. Gastroenterology, By Value (2012-2022)
5.4.4. Oncology, By Value (2012-2022)
5.4.5. Cardiology, By Value (2012-2022)
5.4.6. Others, By Value (2012-2022)
5.5. North America I.V. Iron Drug Market- By Product Type, By Value, (2012-2022)
5.5.1. Ferric carboxymaltose, By Value (2012-2022)
5.5.2. Iron Sucrose, By Value (2012-2022)
5.5.3. Iron Dextran
5.5.4. Others
6. NORTH AMERICA I.V. IRON DRUG MARKET: GROWTH AND FORECAST
6.1. North America I.V. Iron Drug Market, By Value (2012-2016)
6.2. North America I.V. Iron Drug Market, By Value (2017-2022)
6.3. North America I.V. Iron Drug & Market - By Therapeutic Application, By Value
6.3.1. I.V. Iron Drug, By Value, % (2016)
6.3.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
6.4. North America I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
6.4.1. Nephrology, By Value (2012-2022)
6.4.2. Gynecology & Obstetrics, By Value (2012-2022)
6.4.3. Gastroenterology, By Value (2012-2022)
6.4.4. Oncology, By Value (2012-2022)
6.4.5. Cardiology, By Value (2012-2022)
6.4.6. Others, By Value (2012-2022)
6.5. North America I.V. Iron Drug Market- By Product Type, By Value, (2012-2022)
6.5.1. Ferric carboxymaltose, By Value (2012-2022)
6.5.2. Iron Sucrose, By Value (2012-2022)
6.5.3. Iron Dextran
6.5.4. Others
6.6. North America I.V. Iron Drug Market: Country Analysis (U.S., Canada)
6.6.1. North America I.V. Iron Drug Market, Country Share, 2012-2016 (% of Total)
6.6.2. North America I.V. Iron Drug Market, Country Share, 2017-2022 (% of Total)
6.7. U.S. I.V. Iron Drug Market: Growth and Forecast
6.7.1. U.S. I.V. Iron Drug Market, By Value (2012-2016)
6.7.2. U.S. I.V. Iron Drug Market, By Value (2017-2022)
6.8. U.S. I.V. Iron Drug & Market - By Therapeutic Application, By Value
6.8.1. I.V. Iron Drug, By Value, % (2016)
6.8.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
6.9. U.S. I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
6.9.1. Nephrology, By Value (2012-2022)
6.9.2. Gynecology & Obstetrics, By Value (2012-2022)
6.9.3. Gastroenterology, By Value (2012-2022)
6.9.4. Oncology, By Value (2012-2022)
6.9.5. Cardiology, By Value (2012-2022)
6.9.6. Others, By Value (2012-2022)
6.10. Canada I.V. Iron Drug Market: Growth and Forecast
6.10.1. Canada I.V. Iron Drug Market, By Value (2012-2016)
6.10.2. Canada I.V. Iron Drug Market, By Value (2017-2022)
6.11. Canada I.V. Iron Drug & Market - By Therapeutic Application, By Value
6.11.1. I.V. Iron Drug, By Value, % (2016)
6.11.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
6.12. Canada I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
6.12.1. Nephrology, By Value (2012-2022)
6.12.2. Gynecology & Obstetrics, By Value (2012-2022)
6.12.3. Gastroenterology, By Value (2012-2022)
6.12.4. Oncology, By Value (2012-2022)
6.12.5. Cardiology, By Value (2012-2022)
6.12.6. Others, By Value (2012-2022)
7. EUROPE I.V. IRON DRUG MARKET: GROWTH AND FORECAST
7.1. I.V. Iron Drug Market, By Value (2012-2016)
7.2. I.V. Iron Drug Market, By Value (2017-2022)
7.3. Europe I.V. Iron Drug & Market - By Therapeutic Application, By Value
7.3.1. I.V. Iron Drug, By Value, % (2016)
7.3.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
7.4. Europe I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
7.4.1. Nephrology, By Value (2012-2022)
7.4.2. Gynecology & Obstetrics, By Value (2012-2022)
7.4.3. Gastroenterology, By Value (2012-2022)
7.4.4. Oncology, By Value (2012-2022)
7.4.5. Cardiology, By Value (2012-2022)
7.4.6. Others, By Value (2012-2022)
7.5. Europe I.V. Iron Drug Market- By Product Type, By Value, (2012-2022)
7.5.1. Ferric carboxymaltose, By Value (2012-2022)
7.5.2. Iron Sucrose, By Value (2012-2022)
7.5.3. Iron Dextran
7.5.4. Others
7.6. Europe I.V. Iron Drug Market: Country Analysis (U.K., Germany, France, Rest of Europe)
7.6.1. Europe I.V. Iron Drug Market, Country Share, 2012-2016 (% of Total)
7.6.2. Europe I.V. Iron Drug Market, Country Share, 2017-2022 (% of Total)
7.7. U.K. I.V. Iron Drug Market: Growth and Forecast
7.7.1. U.K. I.V. Iron Drug Market, By Value (2012-2016)
7.7.2. U.K. I.V. Iron Drug Market, By Value (2017-2022)
7.8. U.K. I.V. Iron Drug & Market - By Therapeutic Application, By Value
7.8.1. I.V. Iron Drug, By Value, % (2016)
7.8.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
7.9. U.K. I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
7.9.1. Nephrology, By Value (2012-2022)
7.9.2. Gynecology & Obstetrics, By Value (2012-2022)
7.9.3. Gastroenterology, By Value (2012-2022)
7.9.4. Oncology, By Value (2012-2022)
7.9.5. Cardiology, By Value (2012-2022)
7.9.6. Others, By Value (2012-2022)
7.10. Germany I.V. Iron Drug Market: Growth and Forecast
7.10.1. Germany I.V. Iron Drug Market, By Value (2012-2016)
7.10.2. Germany I.V. Iron Drug Market, By Value (2017-2022)
7.11. Germany I.V. Iron Drug & Market - By Therapeutic Application, By Value
7.11.1. I.V. Iron Drug, By Value, % (2016)
7.11.2 I.V. Iron Drug, By Value, % (Forecast 2022F)
7.12. Germany I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
7.12.1. Nephrology, By Value (2012-2022)
7.12.2. Gynecology & Obstetrics, By Value (2012-2022)
7.12.3. Gastroenterology, By Value (2012-2022)
7.12.4. Oncology, By Value (2012-2022)
7.12.5. Cardiology, By Value (2012-2022)
7.12.6. Others, By Value (2012-2022)
7.13. France I.V. Iron Drug Market: Growth and Forecast
7.13.1. France I.V. Iron Drug Market, By Value (2012-2016)
7.13.2. France I.V. Iron Drug Market, By Value (2017-2022)
7.14. France I.V. Iron Drug & Market - By Therapeutic Application, By Value
7.14.1. I.V. Iron Drug, By Value, % (2016)
7.14.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
7.15. France I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
7.15.1. Nephrology, By Value (2012-2022)
7.15.2. Gynecology & Obstetrics, By Value (2012-2022)
7.15.3. Gastroenterology, By Value (2012-2022)
7.15.4. Oncology, By Value (2012-2022)
7.15.5. Cardiology, By Value (2012-2022)
7.15.6. Others, By Value (2012-2022)
7.16. Rest of Europe I.V. Iron Drug Market: Growth and Forecast
7.16.1. Rest of Europe I.V. Iron Drug Market, By Value (2012-2016)
7.16.2. Rest of Europe I.V. Iron Drug Market, By Value (2017-2022)
8. ASIA PACIFIC I.V. IRON DRUG MARKET: GROWTH AND FORECAST
8.1. I.V. Iron Drug Market, By Value (2012-2016)
8.2. I.V. Iron Drug Market, By Value (2017-2022)
8.3. Asia Pacific I.V. Iron Drug & Market - By Therapeutic Application, By Value
8.3.1. I.V. Iron Drug, By Value, % (2016)
8.3.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
8.4. Asia Pacific I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
8.4.1. Nephrology, By Value (2012-2022)
8.4.2. Gynecology & Obstetrics, By Value (2012-2022)
8.4.3. Gastroenterology, By Value (2012-2022)
8.4.4. Oncology, By Value (2012-2022)
8.4.5. Cardiology, By Value (2012-2022)
8.4.6. Others, By Value (2012-2022)
8.5. Asia Pacific I.V. Iron Drug Market- By Product Type, By Value, (2012-2022)
8.5.1. Ferric carboxymaltose, By Value (2012-2022)
8.5.2. Iron Sucrose, By Value (2012-2022)
8.5.3. Iron Dextran
8.5.4. Others
8.6. Asia Pacific I.V. Iron Drug Market: Country Analysis (Japan, China, India, Rest of Asia-Pacific)
8.6.1. Asia Pacific I.V. Iron Drug Market, Country Share, 2012-2016 (% of Total)
8.6.2. Asia Pacific I.V. Iron Drug Market, Country Share, 2017-2022 (% of Total)
8.7. Japan I.V. Iron Drug Market: Growth and Forecast
8.7.1. Japan I.V. Iron Drug Market, By Value (2012-2016)
8.7.2. Japan I.V. Iron Drug Market, By Value (2017-2022)
8.8. Japan I.V. Iron Drug & Market - By Therapeutic Application, By Value
8.8.1. I.V. Iron Drug, By Value, % (2016)
8.8.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
8.9. Japan I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
8.9.1. Nephrology, By Value (2012-2022)
8.9.2. Gynecology & Obstetrics, By Value (2012-2022)
8.9.3. Gastroenterology, By Value (2012-2022)
8.9.4. Oncology, By Value (2012-2022)
8.9.5. Cardiology, By Value (2012-2022)
8.9.6. Others, By Value (2012-2022)
8.10. China I.V. Iron Drug Market: Growth and Forecast
8.10.1. China I.V. Iron Drug Market, By Value (2012-2016)
8.10.2. China I.V. Iron Drug Market, By Value (2017-2022)
8.11. China I.V. Iron Drug & Market - By Therapeutic Application, By Value
8.11.1. I.V. Iron Drug, By Value, % (2016)
8.11.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
8.12. China I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
8.12.1. Nephrology, By Value (2012-2022)
8.12.2. Gynecology & Obstetrics, By Value (2012-2022)
8.12.3. Gastroenterology, By Value (2012-2022)
8.12.4. Oncology, By Value (2012-2022)
8.12.5. Cardiology, By Value (2012-2022)
8.12.6. Others, By Value (2012-2022)
8.13. India I.V. Iron Drug Market: Growth and Forecast
8.13.1. India I.V. Iron Drug Market, By Value (2012-2016)
8.13.2. India I.V. Iron Drug Market, By Value (2017-2022)
8.14. India I.V. Iron Drug & Market - By Therapeutic Application, By Value
8.14.1. I.V. Iron Drug, By Value, % (2016)
8.14.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
8.15. India I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
8.15.1. Nephrology, By Value (2012-2022)
8.15.2. Gynecology & Obstetrics, By Value (2012-2022)
8.15.3. Gastroenterology, By Value (2012-2022)
8.15.4. Oncology, By Value (2012-2022)
8.15.5. Cardiology, By Value (2012-2022)
8.15.6. Others, By Value (2012-2022)
8.16. Rest of Asia Pacific I.V. Iron Drug Market: Growth and Forecast
8.16.1. Rest of Asia Pacific I.V. Iron Drug Market, By Value (2012-2016)
8.16.2. Rest of Asia Pacific I.V. Iron Drug Market, By Value (2017-2022)
9. ROW I.V. IRON DRUG MARKET: GROWTH AND FORECAST
9.1. I.V. Iron Drug Market, By Value (2012-2016)
9.2. I.V. Iron Drug Market, By Value (2017-2022)
9.3. ROW I.V. Iron Drug & Market - By Therapeutic Application, By Value
9.3.1. I.V. Iron Drug, By Value, % (2016)
9.3.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
9.4. ROW I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
9.4.1. Nephrology, By Value (2012-2022)
9.4.2. Gynecology & Obstetrics, By Value (2012-2022)
9.4.3. Gastroenterology, By Value (2012-2022)
9.4.4. Oncology, By Value (2012-2022)
9.4.5. Cardiology, By Value (2012-2022)
9.4.6. Others, By Value (2012-2022)
9.5. ROW I.V. Iron Drug Market- By Product Type, By Value, (2012-2022)
9.5.1. Ferric carboxymaltose, By Value (2012-2022)
9.5.2. Iron Sucrose, By Value (2012-2022)
9.5.3. Iron Dextran
9.5.4. Others
9.6. ROW I.V. Iron Drug Market: Country Analysis (Brazil, South Africa)
9.6.1. ROW I.V. Iron Drug Market, Country Share, 2012-2016 (% of Total)
9.6.2. ROW I.V. Iron Drug Market, Country Share, 2017-2022 (% of Total)
9.7. Brazil I.V. Iron Drug Market: Growth and Forecast
9.7.1. Brazil I.V. Iron Drug Market, By Value (2012-2016)
9.7.2. Brazil I.V. Iron Drug Market, By Value (2017-2022)
9.8. South Africa I.V. Iron Drug Market: Growth and Forecast
9.8.1. South Africa I.V. Iron Drug Market, By Value (2012-2016)
9.8.2. South Africa I.V. Iron Drug Market, By Value (2017-2022)
10. MARKET DYNAMICS
10.1. Increasing Geriatric Population Worldwide
10.2. Increasing awareness about the Iron Deficiency diseases
10.3. Rising healthcare expenditure worldwide
10.4. Increasing number of dialysis patients
10.5. Increasing Life Expectancy
11. MARKET RESTRAINTS
12. SWOT ANALYSIS – I.V. IRON DRUG MARKET
13. PORTER’S FIVE FORCES ANALYSIS – I.V. IRON DRUG MARKET
14. POLICY AND REGULATIONS
15. COMPANY PROFILES
15.1. Galenica
15.2. AMAG Pharmaceuticals, Inc
15.3. PHARMACOSMOS A/S
15.4. Allergan PLC
15.5. Daichi Sankyo Company Ltd.
15.6. Nippon Shinyaku Co. Ltd.
15.7. Sanofi
16. ABOUT US
2. EXECUTIVE SUMMARY
3. STRATEGIC RECOMMENDATIONS
3.1. Asia Pacific Region to witness the fastest growth for I.V. Iron drug in the forecast period
3.2. Oncology & cardiology segments are witnessing fastest growth
4. I.V. IRON DRUG MARKET OUTLOOK
5. GLOBAL I.V. IRON DRUG MARKET: GROWTH AND FORECAST
5.1. I.V. Iron Drug Market, By Value (2012-2016)
5.2. I.V. Iron Drug Market, By Value (2017-2022)
5.3. Global I.V. Iron Drug & Market - By Therapeutic Application, By Value
5.3.1. I.V. Iron Drug, By Value, % (2016)
5.3.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
5.4. Global I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
5.4.1. Nephrology, By Value (2012-2022)
5.4.2. Gynecology & Obstetrics, By Value (2012-2022)
5.4.3. Gastroenterology, By Value (2012-2022)
5.4.4. Oncology, By Value (2012-2022)
5.4.5. Cardiology, By Value (2012-2022)
5.4.6. Others, By Value (2012-2022)
5.5. North America I.V. Iron Drug Market- By Product Type, By Value, (2012-2022)
5.5.1. Ferric carboxymaltose, By Value (2012-2022)
5.5.2. Iron Sucrose, By Value (2012-2022)
5.5.3. Iron Dextran
5.5.4. Others
6. NORTH AMERICA I.V. IRON DRUG MARKET: GROWTH AND FORECAST
6.1. North America I.V. Iron Drug Market, By Value (2012-2016)
6.2. North America I.V. Iron Drug Market, By Value (2017-2022)
6.3. North America I.V. Iron Drug & Market - By Therapeutic Application, By Value
6.3.1. I.V. Iron Drug, By Value, % (2016)
6.3.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
6.4. North America I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
6.4.1. Nephrology, By Value (2012-2022)
6.4.2. Gynecology & Obstetrics, By Value (2012-2022)
6.4.3. Gastroenterology, By Value (2012-2022)
6.4.4. Oncology, By Value (2012-2022)
6.4.5. Cardiology, By Value (2012-2022)
6.4.6. Others, By Value (2012-2022)
6.5. North America I.V. Iron Drug Market- By Product Type, By Value, (2012-2022)
6.5.1. Ferric carboxymaltose, By Value (2012-2022)
6.5.2. Iron Sucrose, By Value (2012-2022)
6.5.3. Iron Dextran
6.5.4. Others
6.6. North America I.V. Iron Drug Market: Country Analysis (U.S., Canada)
6.6.1. North America I.V. Iron Drug Market, Country Share, 2012-2016 (% of Total)
6.6.2. North America I.V. Iron Drug Market, Country Share, 2017-2022 (% of Total)
6.7. U.S. I.V. Iron Drug Market: Growth and Forecast
6.7.1. U.S. I.V. Iron Drug Market, By Value (2012-2016)
6.7.2. U.S. I.V. Iron Drug Market, By Value (2017-2022)
6.8. U.S. I.V. Iron Drug & Market - By Therapeutic Application, By Value
6.8.1. I.V. Iron Drug, By Value, % (2016)
6.8.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
6.9. U.S. I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
6.9.1. Nephrology, By Value (2012-2022)
6.9.2. Gynecology & Obstetrics, By Value (2012-2022)
6.9.3. Gastroenterology, By Value (2012-2022)
6.9.4. Oncology, By Value (2012-2022)
6.9.5. Cardiology, By Value (2012-2022)
6.9.6. Others, By Value (2012-2022)
6.10. Canada I.V. Iron Drug Market: Growth and Forecast
6.10.1. Canada I.V. Iron Drug Market, By Value (2012-2016)
6.10.2. Canada I.V. Iron Drug Market, By Value (2017-2022)
6.11. Canada I.V. Iron Drug & Market - By Therapeutic Application, By Value
6.11.1. I.V. Iron Drug, By Value, % (2016)
6.11.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
6.12. Canada I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
6.12.1. Nephrology, By Value (2012-2022)
6.12.2. Gynecology & Obstetrics, By Value (2012-2022)
6.12.3. Gastroenterology, By Value (2012-2022)
6.12.4. Oncology, By Value (2012-2022)
6.12.5. Cardiology, By Value (2012-2022)
6.12.6. Others, By Value (2012-2022)
7. EUROPE I.V. IRON DRUG MARKET: GROWTH AND FORECAST
7.1. I.V. Iron Drug Market, By Value (2012-2016)
7.2. I.V. Iron Drug Market, By Value (2017-2022)
7.3. Europe I.V. Iron Drug & Market - By Therapeutic Application, By Value
7.3.1. I.V. Iron Drug, By Value, % (2016)
7.3.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
7.4. Europe I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
7.4.1. Nephrology, By Value (2012-2022)
7.4.2. Gynecology & Obstetrics, By Value (2012-2022)
7.4.3. Gastroenterology, By Value (2012-2022)
7.4.4. Oncology, By Value (2012-2022)
7.4.5. Cardiology, By Value (2012-2022)
7.4.6. Others, By Value (2012-2022)
7.5. Europe I.V. Iron Drug Market- By Product Type, By Value, (2012-2022)
7.5.1. Ferric carboxymaltose, By Value (2012-2022)
7.5.2. Iron Sucrose, By Value (2012-2022)
7.5.3. Iron Dextran
7.5.4. Others
7.6. Europe I.V. Iron Drug Market: Country Analysis (U.K., Germany, France, Rest of Europe)
7.6.1. Europe I.V. Iron Drug Market, Country Share, 2012-2016 (% of Total)
7.6.2. Europe I.V. Iron Drug Market, Country Share, 2017-2022 (% of Total)
7.7. U.K. I.V. Iron Drug Market: Growth and Forecast
7.7.1. U.K. I.V. Iron Drug Market, By Value (2012-2016)
7.7.2. U.K. I.V. Iron Drug Market, By Value (2017-2022)
7.8. U.K. I.V. Iron Drug & Market - By Therapeutic Application, By Value
7.8.1. I.V. Iron Drug, By Value, % (2016)
7.8.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
7.9. U.K. I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
7.9.1. Nephrology, By Value (2012-2022)
7.9.2. Gynecology & Obstetrics, By Value (2012-2022)
7.9.3. Gastroenterology, By Value (2012-2022)
7.9.4. Oncology, By Value (2012-2022)
7.9.5. Cardiology, By Value (2012-2022)
7.9.6. Others, By Value (2012-2022)
7.10. Germany I.V. Iron Drug Market: Growth and Forecast
7.10.1. Germany I.V. Iron Drug Market, By Value (2012-2016)
7.10.2. Germany I.V. Iron Drug Market, By Value (2017-2022)
7.11. Germany I.V. Iron Drug & Market - By Therapeutic Application, By Value
7.11.1. I.V. Iron Drug, By Value, % (2016)
7.11.2 I.V. Iron Drug, By Value, % (Forecast 2022F)
7.12. Germany I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
7.12.1. Nephrology, By Value (2012-2022)
7.12.2. Gynecology & Obstetrics, By Value (2012-2022)
7.12.3. Gastroenterology, By Value (2012-2022)
7.12.4. Oncology, By Value (2012-2022)
7.12.5. Cardiology, By Value (2012-2022)
7.12.6. Others, By Value (2012-2022)
7.13. France I.V. Iron Drug Market: Growth and Forecast
7.13.1. France I.V. Iron Drug Market, By Value (2012-2016)
7.13.2. France I.V. Iron Drug Market, By Value (2017-2022)
7.14. France I.V. Iron Drug & Market - By Therapeutic Application, By Value
7.14.1. I.V. Iron Drug, By Value, % (2016)
7.14.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
7.15. France I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
7.15.1. Nephrology, By Value (2012-2022)
7.15.2. Gynecology & Obstetrics, By Value (2012-2022)
7.15.3. Gastroenterology, By Value (2012-2022)
7.15.4. Oncology, By Value (2012-2022)
7.15.5. Cardiology, By Value (2012-2022)
7.15.6. Others, By Value (2012-2022)
7.16. Rest of Europe I.V. Iron Drug Market: Growth and Forecast
7.16.1. Rest of Europe I.V. Iron Drug Market, By Value (2012-2016)
7.16.2. Rest of Europe I.V. Iron Drug Market, By Value (2017-2022)
8. ASIA PACIFIC I.V. IRON DRUG MARKET: GROWTH AND FORECAST
8.1. I.V. Iron Drug Market, By Value (2012-2016)
8.2. I.V. Iron Drug Market, By Value (2017-2022)
8.3. Asia Pacific I.V. Iron Drug & Market - By Therapeutic Application, By Value
8.3.1. I.V. Iron Drug, By Value, % (2016)
8.3.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
8.4. Asia Pacific I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
8.4.1. Nephrology, By Value (2012-2022)
8.4.2. Gynecology & Obstetrics, By Value (2012-2022)
8.4.3. Gastroenterology, By Value (2012-2022)
8.4.4. Oncology, By Value (2012-2022)
8.4.5. Cardiology, By Value (2012-2022)
8.4.6. Others, By Value (2012-2022)
8.5. Asia Pacific I.V. Iron Drug Market- By Product Type, By Value, (2012-2022)
8.5.1. Ferric carboxymaltose, By Value (2012-2022)
8.5.2. Iron Sucrose, By Value (2012-2022)
8.5.3. Iron Dextran
8.5.4. Others
8.6. Asia Pacific I.V. Iron Drug Market: Country Analysis (Japan, China, India, Rest of Asia-Pacific)
8.6.1. Asia Pacific I.V. Iron Drug Market, Country Share, 2012-2016 (% of Total)
8.6.2. Asia Pacific I.V. Iron Drug Market, Country Share, 2017-2022 (% of Total)
8.7. Japan I.V. Iron Drug Market: Growth and Forecast
8.7.1. Japan I.V. Iron Drug Market, By Value (2012-2016)
8.7.2. Japan I.V. Iron Drug Market, By Value (2017-2022)
8.8. Japan I.V. Iron Drug & Market - By Therapeutic Application, By Value
8.8.1. I.V. Iron Drug, By Value, % (2016)
8.8.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
8.9. Japan I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
8.9.1. Nephrology, By Value (2012-2022)
8.9.2. Gynecology & Obstetrics, By Value (2012-2022)
8.9.3. Gastroenterology, By Value (2012-2022)
8.9.4. Oncology, By Value (2012-2022)
8.9.5. Cardiology, By Value (2012-2022)
8.9.6. Others, By Value (2012-2022)
8.10. China I.V. Iron Drug Market: Growth and Forecast
8.10.1. China I.V. Iron Drug Market, By Value (2012-2016)
8.10.2. China I.V. Iron Drug Market, By Value (2017-2022)
8.11. China I.V. Iron Drug & Market - By Therapeutic Application, By Value
8.11.1. I.V. Iron Drug, By Value, % (2016)
8.11.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
8.12. China I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
8.12.1. Nephrology, By Value (2012-2022)
8.12.2. Gynecology & Obstetrics, By Value (2012-2022)
8.12.3. Gastroenterology, By Value (2012-2022)
8.12.4. Oncology, By Value (2012-2022)
8.12.5. Cardiology, By Value (2012-2022)
8.12.6. Others, By Value (2012-2022)
8.13. India I.V. Iron Drug Market: Growth and Forecast
8.13.1. India I.V. Iron Drug Market, By Value (2012-2016)
8.13.2. India I.V. Iron Drug Market, By Value (2017-2022)
8.14. India I.V. Iron Drug & Market - By Therapeutic Application, By Value
8.14.1. I.V. Iron Drug, By Value, % (2016)
8.14.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
8.15. India I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
8.15.1. Nephrology, By Value (2012-2022)
8.15.2. Gynecology & Obstetrics, By Value (2012-2022)
8.15.3. Gastroenterology, By Value (2012-2022)
8.15.4. Oncology, By Value (2012-2022)
8.15.5. Cardiology, By Value (2012-2022)
8.15.6. Others, By Value (2012-2022)
8.16. Rest of Asia Pacific I.V. Iron Drug Market: Growth and Forecast
8.16.1. Rest of Asia Pacific I.V. Iron Drug Market, By Value (2012-2016)
8.16.2. Rest of Asia Pacific I.V. Iron Drug Market, By Value (2017-2022)
9. ROW I.V. IRON DRUG MARKET: GROWTH AND FORECAST
9.1. I.V. Iron Drug Market, By Value (2012-2016)
9.2. I.V. Iron Drug Market, By Value (2017-2022)
9.3. ROW I.V. Iron Drug & Market - By Therapeutic Application, By Value
9.3.1. I.V. Iron Drug, By Value, % (2016)
9.3.2. I.V. Iron Drug, By Value, % (Forecast 2022F)
9.4. ROW I.V. Iron Drug & Market- By Therapeutic Application, By Value (2012-2022)
9.4.1. Nephrology, By Value (2012-2022)
9.4.2. Gynecology & Obstetrics, By Value (2012-2022)
9.4.3. Gastroenterology, By Value (2012-2022)
9.4.4. Oncology, By Value (2012-2022)
9.4.5. Cardiology, By Value (2012-2022)
9.4.6. Others, By Value (2012-2022)
9.5. ROW I.V. Iron Drug Market- By Product Type, By Value, (2012-2022)
9.5.1. Ferric carboxymaltose, By Value (2012-2022)
9.5.2. Iron Sucrose, By Value (2012-2022)
9.5.3. Iron Dextran
9.5.4. Others
9.6. ROW I.V. Iron Drug Market: Country Analysis (Brazil, South Africa)
9.6.1. ROW I.V. Iron Drug Market, Country Share, 2012-2016 (% of Total)
9.6.2. ROW I.V. Iron Drug Market, Country Share, 2017-2022 (% of Total)
9.7. Brazil I.V. Iron Drug Market: Growth and Forecast
9.7.1. Brazil I.V. Iron Drug Market, By Value (2012-2016)
9.7.2. Brazil I.V. Iron Drug Market, By Value (2017-2022)
9.8. South Africa I.V. Iron Drug Market: Growth and Forecast
9.8.1. South Africa I.V. Iron Drug Market, By Value (2012-2016)
9.8.2. South Africa I.V. Iron Drug Market, By Value (2017-2022)
10. MARKET DYNAMICS
10.1. Increasing Geriatric Population Worldwide
10.2. Increasing awareness about the Iron Deficiency diseases
10.3. Rising healthcare expenditure worldwide
10.4. Increasing number of dialysis patients
10.5. Increasing Life Expectancy
11. MARKET RESTRAINTS
12. SWOT ANALYSIS – I.V. IRON DRUG MARKET
13. PORTER’S FIVE FORCES ANALYSIS – I.V. IRON DRUG MARKET
14. POLICY AND REGULATIONS
15. COMPANY PROFILES
15.1. Galenica
15.2. AMAG Pharmaceuticals, Inc
15.3. PHARMACOSMOS A/S
15.4. Allergan PLC
15.5. Daichi Sankyo Company Ltd.
15.6. Nippon Shinyaku Co. Ltd.
15.7. Sanofi
16. ABOUT US
LIST OF FIGURES
Figure 1: Causes of premature (under age 70) NCD mortality, 2017 (%)
Figure 2: Global I.V. Iron Drug Market Size, By Value, 2012-2016 (USD Million)
Figure 3: World Population 65 Years & Above (% of Total), 2012-2016
Figure 4: Life Expectancy at birth rate (Years), 2012-2015
Figure 5: Global Life expectancy at birth, total (years) 2012 -2015
Figure 6: World Female Population, 2012-2016
Figure 7: Global Healthcare Expenditure, 2012-2016 (In Trillion)
Figure 8: Global Potential Patients Numbers, All Indications 2017 (In Million)
Figure 9: Global I.V. Iron Drug Market Size, By Value, Forecast, 2017-2022 (USD Million)
Figure 10: Global I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 11: Global I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 12: Global I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 13: Worldwide Dialysis Patients, Numbers (In Million), 2010, 2015, 2020
Figure 14: Global I.V. Iron Drug Market- By Product Type, By Value, 2012-2022 (USD Million)
Figure 15: Global I.V. Iron Drug Market- By Product Type, By Value, 2012-2022 (USD Million)
Figure 16: North America I.V. Iron Drug Market Size, By Value, 2012-2016 (USD Million)
Figure 17: North America Population 65 Years & Above (% of Total), 2012-2016
Figure 18: North America Life Expectancy at birth rate (Years), 2012-2015
Figure 19: North America Women Population, 2012-2016
Figure 20: North America, Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 21: Population aged 65 & above, 2012-2016 (% of total)
Figure 22: North America I.V. Iron Drug Market Size, By Value, Forecast, 2017-2022 (USD Million)
Figure 23: North America I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 24: North America I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 25: North America I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 26: North America I.V. Iron Drug Market - By Product Type, By Value, 2012-2022 (USD Million)
Figure 27: North America I.V. Iron Drug Market, Country Share, 2016 (% of Total)
Figure 28: North America I.V. Iron Drug Market, Country Share, 2022 (% of Total)
Figure 29: U.S. I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 30: U.S. Population 65 Years & Above (% of Total), 2012-2016
Figure 31: U.S. Life Expectancy at birth rate (Years), 2012-2015
Figure 32: U.S. Women Population, 2012-2016
Figure 33: U.S. Per Capita Healthcare Expenditure, 2012-2014 (In Trillion)
Figure 34: United States I.V. Iron Drug Market- By Product Type, By Value, 2012-2022 (USD Million)
Figure 35: U.S. I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 36: U.S. I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 37: U.S. I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 38: Canada I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 39: Canada Population 65 Years & Above (% of Total), 2012-2016
Figure 40: Canada Life Expectancy at birth rate (Years), 2012-2015
Figure 41: Canada Women Population, 2012-2016
Figure 42: End Stage Kidney Disease patients by Age group, 2012-2015 (Numbers)
Figure 43: Prevalent end-stage kidney disease patients by age group, Canada (excluding Quebec), 2012-2015 (Numbers)
Figure 44: Prevalence rate for patients on dialysis (Excluding Quebec), 2012-2015
Figure 45: Prevalent rate for patients on dialysis or with a functioning transplant in Canada (excluding Quebec), 2012-2015
Figure 46: Canada I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 47: Canada I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 48: Canada I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 49: Europe I.V. Iron Drug Market Size, By Value, 2012-2016 (USD Million)
Figure 50: European Union Population 65 Years & Above (% of Total), 2012-2016
Figure 51: European Union Life Expectancy at birth rate (Years), 2012-2015
Figure 52: European Union Women Population, 2012-2016
Figure 53: European Union, Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 54: European Potential Patients Numbers, All Indications 2017 (In Million)
Figure 55: Europe I.V. Iron Drug Market Size, By Value, Forecast, 2017-2022 (USD Million)
Figure 56: Europe I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 57: Europe I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 58: Europe I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 59: Europe I.V. Iron Drug Market - By Product Type, By Value, 2012-2022, (USD Million)
Figure 60: Europe I.V. Iron Drug Market- By Product Type, By Value, 2012-2022 (USD Million)
Figure 61: Europe I.V. Iron Drug Market, Country Share, 2016 (% of Total)
Figure 62: Europe I.V. Iron Drug Market, Country Share, 2022 (% of Total)
Figure 63: U.K. I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 64: U.K. Population 65 Years & Above (% of Total), 2012-2016
Figure 65: U.K. Life Expectancy at birth rate (Years), 2012-2015
Figure 66: U.K. Women Population, 2012-2016
Figure 67: U.K., Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 68: U.K. I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 69: U.K. I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 70: U.K. I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 71: Germany I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 72: Germany Population 65 Years & Above (% of Total), 2012-2016
Figure 73: Germany Life Expectancy at birth rate (Years), 2012-2015
Figure 74: Germany Women Population, 2012-2016
Figure 75: Germany Per Capita Healthcare Expenditure, 2012 - 2014 (In USD)
Figure 76: Germany I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 77: Germany I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 78: Germany I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 79: France I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 80: France Population 65 Years & Above (% of Total), 2012-2016
Figure 81: France Life Expectancy at birth rate (Years), 2012-2015
Figure 82: France Women Population, 2012-2016
Figure 83: France Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 84: France I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 85: France I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 86: France I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 87: Rest of Europe I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 88: Asia-Pacific I.V. Iron Drug Market Size, By Value, 2012-2016 (USD Million)
Figure 89: Asia-Pacific I.V. Iron Drug Market Size, By Value, Forecast, 2017-2022 (USD Million)
Figure 90: Asia-Pacific I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 91: Asia-Pacific I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 92: Asia-Pacific I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 93: Asia-Pacific I.V. Iron Drug Market - By Product Type, By Value, 2012-2022 (USD Million)
Figure 94: Asia-Pacific I.V. Iron Drug Market, Country Share, 2016 (% of Total)
Figure 95: Asia-Pacific I.V. Iron Drug Market, Country Share, 2022 (% of Total)
Figure 96: Japan I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 97: Japan Population 65 Years & Above (% of Total), 2012-2016
Figure 98: Japan Life Expectancy at birth rate (Years), 2012-2015
Figure 99: Japan, Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 100: Japan I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 101: Japan I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 102: Japan I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 103: China I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 104: China Population 65 Years & Above (% of Total), 2012-2016
Figure 105: China Life Expectancy at birth rate (Years), 2012-2015
Figure 106: China Women Population, 2012-2016
Figure 107: China Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 108: China I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 109: China I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 110: China I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 111: Registered Number Dialysis patients in China (In ten thousands), 2012-2016
Figure 112: India I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 113: India Population 65 Years & Above (% of Total), 2012-2016
Figure 114: India Life Expectancy at birth rate (Years), 2012-2015
Figure 115: India Women Population, 2012-2016
Figure 116: India Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 117: India I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 118: India I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 119: India I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 120: Rest of Asia-Pacific I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 121: ROW I.V. Iron Drug Market Size, By Value, 2012-2016 (USD Million)
Figure 122: ROW I.V. Iron Drug Market Size, By Value, Forecast, 2017-2022 (USD Million)
Figure 123: ROW I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 124: ROW I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 125: ROW I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 126: ROW I.V. Iron Drug Market - By Product Type, By Value, 2012-2022 (USD Million)
Figure 127: ROW I.V. Iron Drug Market, Country Share, 2016 (% of Total)
Figure 128: ROW I.V. Iron Drug Market, Country Share, 2022 (% of Total)
Figure 129: Brazil I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 130: Brazil Population 65 Years & Above (% of Total), 2012-2016
Figure 131: Brazil Life Expectancy at birth rate (Years), 2012-2015
Figure 132: Brazil Women Population, 2012-2016
Figure 133: Brazil, Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 134: South Africa I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 135: South Africa Population 65 Years & Above (% of Total), 2012-2016
Figure 136: South Africa Life Expectancy at birth rate (Years), 2012-2015
Figure 137: South Africa Women Population, 2012-2016
Figure 138: South Africa Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 139: Percentage aged 60 years and over, (2000, 2015, 2030, 2050)
Figure 140: Global Healthcare Expenditure, 2012-2016 (In Trillion)
Figure 141: Global Dialysis Patients, By Dialysis, 2016, (% Share)
Figure 142: Global Dialysis Patients, 2012 -2016, Million
Figure 143: Global Life expectancy at birth, total (years) 1990-2100
Figure 144: Net Sales, By Business Unit, 2016 (%)
Figure 145: Net Sales, By Region, 2016 (%)
Figure 146: Revenue, 2013-2016 (USD Million)
Figure 147: AMAG Pharmaceuticals, Inc. Revenue (USD Million) 2012-2016
Figure 148: Net Sales, By Business Unit, 2016 (%)
Figure 149: AMAG Pharmaceuticals, Inc. Revenue (USD Million) 2014-2016
Figure 150: Net Sales, By Business Unit, 2016 (%)
Figure 151: Daichi Sankyo Company Ltd. Revenue, By Business segment, 2016 (%)
Figure 152: Daichi Sankyo Company Ltd. JAPAN BUSINESS, By Revenues, By Business segment, 2016 (%)
Figure 153: Daichi Sankyo Company Ltd.Revenue (USD Million) 2012-2016
Figure 154: Nippon Shinyaku Co. Ltd. By Revenues, By Business segment, % Share Year Ending March 31st 2017 (%)
Figure 155: Nippon Shinyaku Co. Ltd. Revenue (USD Million) 2013-2017, Year Ending March 31st 2017
Figure 156: Nippon Shinyaku Co. Ltd. Revenue, By Geography, % Share, Year Ending March 31st 2017
Figure 157: Nippon Shinyaku Co. Ltd. R & D Expenses, 2016 (%)
Figure 158: Sanofi Revenue, By Business segment, 2016 (%)
Figure 159: Sanofi BUSINESS, By, Revenues, By Business segment, 2016 (%)
Figure 160: Sanofi Revenue (USD Million) 2012-2016
Figure 1: Causes of premature (under age 70) NCD mortality, 2017 (%)
Figure 2: Global I.V. Iron Drug Market Size, By Value, 2012-2016 (USD Million)
Figure 3: World Population 65 Years & Above (% of Total), 2012-2016
Figure 4: Life Expectancy at birth rate (Years), 2012-2015
Figure 5: Global Life expectancy at birth, total (years) 2012 -2015
Figure 6: World Female Population, 2012-2016
Figure 7: Global Healthcare Expenditure, 2012-2016 (In Trillion)
Figure 8: Global Potential Patients Numbers, All Indications 2017 (In Million)
Figure 9: Global I.V. Iron Drug Market Size, By Value, Forecast, 2017-2022 (USD Million)
Figure 10: Global I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 11: Global I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 12: Global I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 13: Worldwide Dialysis Patients, Numbers (In Million), 2010, 2015, 2020
Figure 14: Global I.V. Iron Drug Market- By Product Type, By Value, 2012-2022 (USD Million)
Figure 15: Global I.V. Iron Drug Market- By Product Type, By Value, 2012-2022 (USD Million)
Figure 16: North America I.V. Iron Drug Market Size, By Value, 2012-2016 (USD Million)
Figure 17: North America Population 65 Years & Above (% of Total), 2012-2016
Figure 18: North America Life Expectancy at birth rate (Years), 2012-2015
Figure 19: North America Women Population, 2012-2016
Figure 20: North America, Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 21: Population aged 65 & above, 2012-2016 (% of total)
Figure 22: North America I.V. Iron Drug Market Size, By Value, Forecast, 2017-2022 (USD Million)
Figure 23: North America I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 24: North America I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 25: North America I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 26: North America I.V. Iron Drug Market - By Product Type, By Value, 2012-2022 (USD Million)
Figure 27: North America I.V. Iron Drug Market, Country Share, 2016 (% of Total)
Figure 28: North America I.V. Iron Drug Market, Country Share, 2022 (% of Total)
Figure 29: U.S. I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 30: U.S. Population 65 Years & Above (% of Total), 2012-2016
Figure 31: U.S. Life Expectancy at birth rate (Years), 2012-2015
Figure 32: U.S. Women Population, 2012-2016
Figure 33: U.S. Per Capita Healthcare Expenditure, 2012-2014 (In Trillion)
Figure 34: United States I.V. Iron Drug Market- By Product Type, By Value, 2012-2022 (USD Million)
Figure 35: U.S. I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 36: U.S. I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 37: U.S. I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 38: Canada I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 39: Canada Population 65 Years & Above (% of Total), 2012-2016
Figure 40: Canada Life Expectancy at birth rate (Years), 2012-2015
Figure 41: Canada Women Population, 2012-2016
Figure 42: End Stage Kidney Disease patients by Age group, 2012-2015 (Numbers)
Figure 43: Prevalent end-stage kidney disease patients by age group, Canada (excluding Quebec), 2012-2015 (Numbers)
Figure 44: Prevalence rate for patients on dialysis (Excluding Quebec), 2012-2015
Figure 45: Prevalent rate for patients on dialysis or with a functioning transplant in Canada (excluding Quebec), 2012-2015
Figure 46: Canada I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 47: Canada I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 48: Canada I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 49: Europe I.V. Iron Drug Market Size, By Value, 2012-2016 (USD Million)
Figure 50: European Union Population 65 Years & Above (% of Total), 2012-2016
Figure 51: European Union Life Expectancy at birth rate (Years), 2012-2015
Figure 52: European Union Women Population, 2012-2016
Figure 53: European Union, Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 54: European Potential Patients Numbers, All Indications 2017 (In Million)
Figure 55: Europe I.V. Iron Drug Market Size, By Value, Forecast, 2017-2022 (USD Million)
Figure 56: Europe I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 57: Europe I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 58: Europe I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 59: Europe I.V. Iron Drug Market - By Product Type, By Value, 2012-2022, (USD Million)
Figure 60: Europe I.V. Iron Drug Market- By Product Type, By Value, 2012-2022 (USD Million)
Figure 61: Europe I.V. Iron Drug Market, Country Share, 2016 (% of Total)
Figure 62: Europe I.V. Iron Drug Market, Country Share, 2022 (% of Total)
Figure 63: U.K. I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 64: U.K. Population 65 Years & Above (% of Total), 2012-2016
Figure 65: U.K. Life Expectancy at birth rate (Years), 2012-2015
Figure 66: U.K. Women Population, 2012-2016
Figure 67: U.K., Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 68: U.K. I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 69: U.K. I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 70: U.K. I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 71: Germany I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 72: Germany Population 65 Years & Above (% of Total), 2012-2016
Figure 73: Germany Life Expectancy at birth rate (Years), 2012-2015
Figure 74: Germany Women Population, 2012-2016
Figure 75: Germany Per Capita Healthcare Expenditure, 2012 - 2014 (In USD)
Figure 76: Germany I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 77: Germany I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 78: Germany I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 79: France I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 80: France Population 65 Years & Above (% of Total), 2012-2016
Figure 81: France Life Expectancy at birth rate (Years), 2012-2015
Figure 82: France Women Population, 2012-2016
Figure 83: France Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 84: France I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 85: France I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 86: France I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 87: Rest of Europe I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 88: Asia-Pacific I.V. Iron Drug Market Size, By Value, 2012-2016 (USD Million)
Figure 89: Asia-Pacific I.V. Iron Drug Market Size, By Value, Forecast, 2017-2022 (USD Million)
Figure 90: Asia-Pacific I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 91: Asia-Pacific I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 92: Asia-Pacific I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 93: Asia-Pacific I.V. Iron Drug Market - By Product Type, By Value, 2012-2022 (USD Million)
Figure 94: Asia-Pacific I.V. Iron Drug Market, Country Share, 2016 (% of Total)
Figure 95: Asia-Pacific I.V. Iron Drug Market, Country Share, 2022 (% of Total)
Figure 96: Japan I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 97: Japan Population 65 Years & Above (% of Total), 2012-2016
Figure 98: Japan Life Expectancy at birth rate (Years), 2012-2015
Figure 99: Japan, Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 100: Japan I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 101: Japan I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 102: Japan I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 103: China I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 104: China Population 65 Years & Above (% of Total), 2012-2016
Figure 105: China Life Expectancy at birth rate (Years), 2012-2015
Figure 106: China Women Population, 2012-2016
Figure 107: China Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 108: China I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 109: China I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 110: China I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 111: Registered Number Dialysis patients in China (In ten thousands), 2012-2016
Figure 112: India I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 113: India Population 65 Years & Above (% of Total), 2012-2016
Figure 114: India Life Expectancy at birth rate (Years), 2012-2015
Figure 115: India Women Population, 2012-2016
Figure 116: India Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 117: India I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 118: India I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 119: India I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 120: Rest of Asia-Pacific I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 121: ROW I.V. Iron Drug Market Size, By Value, 2012-2016 (USD Million)
Figure 122: ROW I.V. Iron Drug Market Size, By Value, Forecast, 2017-2022 (USD Million)
Figure 123: ROW I.V. Iron Drug Market Size, By Therapeutic Application, 2016 (%)
Figure 124: ROW I.V. Iron Drug Market Size, By Therapeutic Application, 2022 (%)
Figure 125: ROW I.V. Iron Drug Market- By Therapeutic Application, By Value 2012-2022 (USD Million)
Figure 126: ROW I.V. Iron Drug Market - By Product Type, By Value, 2012-2022 (USD Million)
Figure 127: ROW I.V. Iron Drug Market, Country Share, 2016 (% of Total)
Figure 128: ROW I.V. Iron Drug Market, Country Share, 2022 (% of Total)
Figure 129: Brazil I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 130: Brazil Population 65 Years & Above (% of Total), 2012-2016
Figure 131: Brazil Life Expectancy at birth rate (Years), 2012-2015
Figure 132: Brazil Women Population, 2012-2016
Figure 133: Brazil, Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 134: South Africa I.V. Iron Drug Market Size, By Value, 2012-2022 (USD Million)
Figure 135: South Africa Population 65 Years & Above (% of Total), 2012-2016
Figure 136: South Africa Life Expectancy at birth rate (Years), 2012-2015
Figure 137: South Africa Women Population, 2012-2016
Figure 138: South Africa Per Capita Healthcare Expenditure, 2012-2014 (In USD)
Figure 139: Percentage aged 60 years and over, (2000, 2015, 2030, 2050)
Figure 140: Global Healthcare Expenditure, 2012-2016 (In Trillion)
Figure 141: Global Dialysis Patients, By Dialysis, 2016, (% Share)
Figure 142: Global Dialysis Patients, 2012 -2016, Million
Figure 143: Global Life expectancy at birth, total (years) 1990-2100
Figure 144: Net Sales, By Business Unit, 2016 (%)
Figure 145: Net Sales, By Region, 2016 (%)
Figure 146: Revenue, 2013-2016 (USD Million)
Figure 147: AMAG Pharmaceuticals, Inc. Revenue (USD Million) 2012-2016
Figure 148: Net Sales, By Business Unit, 2016 (%)
Figure 149: AMAG Pharmaceuticals, Inc. Revenue (USD Million) 2014-2016
Figure 150: Net Sales, By Business Unit, 2016 (%)
Figure 151: Daichi Sankyo Company Ltd. Revenue, By Business segment, 2016 (%)
Figure 152: Daichi Sankyo Company Ltd. JAPAN BUSINESS, By Revenues, By Business segment, 2016 (%)
Figure 153: Daichi Sankyo Company Ltd.Revenue (USD Million) 2012-2016
Figure 154: Nippon Shinyaku Co. Ltd. By Revenues, By Business segment, % Share Year Ending March 31st 2017 (%)
Figure 155: Nippon Shinyaku Co. Ltd. Revenue (USD Million) 2013-2017, Year Ending March 31st 2017
Figure 156: Nippon Shinyaku Co. Ltd. Revenue, By Geography, % Share, Year Ending March 31st 2017
Figure 157: Nippon Shinyaku Co. Ltd. R & D Expenses, 2016 (%)
Figure 158: Sanofi Revenue, By Business segment, 2016 (%)
Figure 159: Sanofi BUSINESS, By, Revenues, By Business segment, 2016 (%)
Figure 160: Sanofi Revenue (USD Million) 2012-2016
LIST OF TABLES
Table A: Available I.V. Iron formulations approved for use throughout the world
Table B: Percentage of patients receiving chemotherapy as a part of their primary treatment, Persons, all ages, England 2013-2014
Table A: Available I.V. Iron formulations approved for use throughout the world
Table B: Percentage of patients receiving chemotherapy as a part of their primary treatment, Persons, all ages, England 2013-2014
